Dopamine in platelets in patients with paragangliomas/pheochromocytoma

Completed

• Conditions: Head and neck paraganglioma; pheochromocytoma; tumor of the adrenal medulla; 10029112; 10014710

• Registration Number: NL-OMON35567
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-05-26
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 122

Inclusion Criteria

1. 18 years of age or older
2. Patients with diagnosed or clinically suspected PGLs and/or pheochromocytomas.
a. Diagnosis of pheochromocytoma and sympathetic PGL (golden standard):
i. Histology postoperative or;
ii. Hypertension and;
iii. Elevated plasma and/or urinary (nor)metanephrines and;
iv. Localization of pheochromocytoma with anatomical imaging (computed tomography (CT)/ Magnetic Resonance Imaging (MRI)) and functional imaging including ¹²³I- metaiodobenzylguanidin (MIBG) scintigraphy or 18F- dihydroxyphenylalanine (DOPA) positron emission tomography (PET).
b. Diagnosis of a HNPGL (golden standard):
i. Postoperative histology or;
ii. Clinical symptoms and;
iii. Localization of a HNPGL with anatomical imaging (CT/MRI) and nuclear imaging including ¹¹¹-In-octreotide/ ¹²³I-MIBG scintigraphy or DOPA-PET.
c. Suspected PGL:
i. Patients with a proven SDH-mutation

Exclusion Criteria

1. < 18 years

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The sensitivity of platelet levels of dopamine in platelets rich plasma in<br /><br>patients with HNPGL compared to the defined golden standard</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Sensitivity (and specificity) in patients with suspected PGL and<br /><br>pheochromocytoma compared to the golden standard</p><br>